
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4636301/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. Journal of Clinical Oncology, 2016, 34, 2888-2898.	1.6	349
2	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
3	Statistical methods for studying disease subtype heterogeneity. Statistics in Medicine, 2016, 35, 782-800.	1.6	204
4	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	6.3	186
5	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
6	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111
7	A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. International Journal of Cancer, 2016, 138, 2088-2097.	5.1	95
8	A Prospective Study of Circulating C-Reactive Protein, Interleukin-6, and Tumor Necrosis Factor α Receptor 2 Levels and Risk of Ovarian Cancer. American Journal of Epidemiology, 2013, 178, 1256-1264.	3.4	85
9	Postdiagnosis social networks and breast cancer mortality in the After Breast Cancer Pooling Project. Cancer, 2017, 123, 1228-1237.	4.1	73
10	Sleep and survival among women with breast cancer: 30 years of follow-up within the Nurses' Health Study. British Journal of Cancer, 2017, 116, 1239-1246.	6.4	70
11	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
12	Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut, 2011, 60, 491-498.	12.1	64
13	Body Size in Early Life and Adult Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3. American Journal of Epidemiology, 2011, 174, 642-651.	3.4	62
14	Postdiagnosis Alcohol Consumption and Breast Cancer Prognosis in the After Breast Cancer Pooling Project. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 32-41.	2.5	59
15	Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Research and Treatment, 2013, 139, 529-537.	2.5	55
16	Rotating Night Shift Work and Risk of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 934-938.	2.5	50
17	Prostacyclin Synthase and Arachidonate 5-Lipoxygenase Polymorphisms and Risk of Colorectal Polyps. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 502-508.	2.5	48
18	Genetic variation in Câ€reactive protein in relation to colon and rectal cancer risk and survival. International lournal of Cancer, 2011, 128, 2726-2734.	5.1	47

#	Article	IF	CITATIONS
19	Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies. JAMA Oncology, 2018, 4, 1675.	7.1	47
20	PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, and FLAP SNPs: interaction with fatty acids in colon cancer and rectal cancer. Genes and Nutrition, 2013, 8, 115-126.	2.5	46
21	Geneâ€dietâ€interactions in folateâ€mediated oneâ€carbon metabolism modify colon cancer risk. Molecular Nutrition and Food Research, 2013, 57, 721-734.	3.3	46
22	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
23	lκBKβ and NFκB1 , NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. Carcinogenesis, 2013, 34, 79-85.	2.8	43
24	Metabolic, hormonal and immunological associations with global DNA methylation among postmenopausal women. Epigenetics, 2012, 7, 1020-1028.	2.7	39
25	COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations. Cancer Causes and Control, 2013, 24, 2059-2075.	1.8	38
26	Folateâ€mediated oneâ€carbon metabolism genes and interactions with nutritional factors on colorectal cancer risk: <scp>W</scp> omen's <scp>H</scp> ealth <scp>I</scp> nitiative <scp>O</scp> bservational <scp>S</scp> tudy. Cancer, 2015, 121, 3684-3691.	4.1	38
27	High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium. Cancer Research, 2019, 79, 5442-5451.	0.9	36
28	ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2012, 23, 1805-1810.	1.8	35
29	The After Breast Cancer Pooling Project: rationale, methodology, and breast cancer survivor characteristics. Cancer Causes and Control, 2011, 22, 1319-1331.	1.8	34
30	Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia. Genes Chromosomes and Cancer, 2013, 52, 437-449.	2.8	34
31	Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps. Carcinogenesis, 2007, 28, 1259-1263.	2.8	30
32	Postâ€diagnosis social networks, and lifestyle and treatment factors in the After Breast Cancer Pooling Project. Psycho-Oncology, 2017, 26, 544-552.	2.3	30
33	Social integration and survival after diagnosis of colorectal cancer. Cancer, 2018, 124, 833-840.	4.1	29
34	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
35	Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium. International Journal of Cancer, 2019, 145, 58-69.	5.1	28
36	Prognostic implications of reproductive and lifestyle factors in ovarian cancer. Gynecologic Oncology, 2016, 142, 574-587.	1.4	27

#	Article	IF	CITATIONS
37	Genetic variation in <i>UGT</i> genes modify the associations of NSAIDs with risk of colorectal cancer: Colon cancer family registry. Genes Chromosomes and Cancer, 2014, 53, 568-578.	2.8	25
38	The inflammatory potential of diet and ovarian cancer risk: results from two prospective cohort studies. British Journal of Cancer, 2017, 117, 907-911.	6.4	25
39	Genetic Variation in Prostaglandin E2 Synthesis and Signaling, Prostaglandin Dehydrogenase, and the Risk of Colorectal Adenoma. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 547-557.	2.5	24
40	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
41	A lipid-related metabolomic pattern of diet quality. American Journal of Clinical Nutrition, 2020, 112, 1613-1630.	4.7	23
42	Polymorphisms in WNT6 and WNT10A and Colorectal Adenoma Risk. Nutrition and Cancer, 2011, 63, 558-564.	2.0	22
43	Psychological symptoms and subsequent healthy lifestyle after a colorectal cancer diagnosis Health Psychology, 2018, 37, 207-217.	1.6	22
44	Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry. Carcinogenesis, 2014, 35, 2121-2126.	2.8	20
45	Genetic Variation in Inflammatory Pathways Is Related to Colorectal Cancer Survival. Clinical Cancer Research, 2011, 17, 7139-7147.	7.0	19
46	Glutathione peroxidase tagSNPs: Associations with rectal cancer but not with colon cancer. Genes Chromosomes and Cancer, 2012, 51, 598-605.	2.8	19
47	Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin. International Journal of Cancer, 2013, 133, 730-739.	5.1	18
48	Thromboxane synthase (TBXAS1) polymorphisms in African-American and Caucasian populations: evidence for selective pressure. Human Mutation, 2005, 26, 394-395.	2.5	17
49	Genetic variability in IL23R and risk of colorectal adenoma and colorectal cancer. Cancer Epidemiology, 2012, 36, e104-e110.	1.9	17
50	Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial. Pharmacogenetics and Genomics, 2013, 23, 428-437.	1.5	15
51	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
52	Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 300-15.	0.4	14
53	CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. Cancer Causes and Control, 2013, 24, 47-54.	1.8	12
54	Genetic PolymorphismCYP17rs2486758 and Metabolic Risk Factors Predict Daily Salivary 17β-Estradiol Concentration in Healthy Premenopausal Norwegian Women. The EBBA-I Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E852-E857.	3.6	11

#	Article	lF	CITATIONS
55	Surrogates of Long-Term Vitamin D Exposure and Ovarian Cancer Risk in Two Prospective Cohort Studies. Cancers, 2013, 5, 1577-1600.	3.7	11
56	Salpingectomy as a Potential Ovarian Cancer Risk-Reducing Procedure. Journal of the National Cancer Institute, 2015, 107, dju490-dju490.	6.3	10
57	Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1. Pharmacogenetics and Genomics, 2012, 22, 525-537.	1.5	9
58	Functional analysis of human thromboxane synthase polymorphic variants. Pharmacogenetics and Genomics, 2012, 22, 653-658.	1.5	8
59	Genetic variability in IGF-1 and IGFBP-3 and body size in early life. BMC Public Health, 2012, 12, 659.	2.9	6
60	Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. Cancer Causes and Control, 2017, 28, 429-435.	1.8	3
61	Post-diagnosis BMI and physical activity in association with triple-negative breast cancer prognosis: Results from 5 prospective cohorts Journal of Clinical Oncology, 2015, 33, 1507-1507.	1.6	1
62	Postdiagnosis social networks and lifestyle and treatment mechanisms in the Ater Breast Cancer Pooling Project (ABCPP) Journal of Clinical Oncology, 2014, 32, 115-115.	1.6	0